<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Edx Medical Group Plc — News on 6ix</title>
<link>https://6ix.com/company/edx-medical-group-plc</link>
<description>Latest news and press releases for Edx Medical Group Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 16:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/edx-medical-group-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d57d7cbeedb30cb6f8955f.webp</url>
<title>Edx Medical Group Plc</title>
<link>https://6ix.com/company/edx-medical-group-plc</link>
</image>
<item>
<title>Granting of options over ordinary shares</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/granting-of-options-over-ordinary-shares</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/granting-of-options-over-ordinary-shares</guid>
<pubDate>Tue, 21 Apr 2026 16:30:00 GMT</pubDate>
<description>EDX Medical Group plc has granted options over ordinary shares to directors and senior management, including Deputy Chairman Martin Walton, Chief Financial Officer Shafia Zahoor, Chief Scientific Officer Professor Sir Christopher Evans, Non-Executive Chairman Jason Holt, and Non-Executive Director Professor Trevor Jones. These options were granted under the company's Non-Enterprise Management Incentive Plan and Enterprise Management Incentive Plan, with a total of 9,750,000 options granted to Mr</description>
</item>
<item>
<title>Proposed application for admission to AIM</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/proposed-application-for-admission-to-aim</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/proposed-application-for-admission-to-aim</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>EDX Medical Group PLC is proposing to move its listing from the Aquis Stock Exchange to AIM, with dealings expected to commence on May 13, 2026. The company anticipates reporting revenue of approximately £1.2 million for the year ended March 31, 2026, a significant increase from the prior year, and ended the year with cash reserves of approximately £2.9 million. To support future growth, EDX Medical has secured a working capital facility of up to £3.71 million from Sir Christopher Evans, in addi</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/total-voting-rights-918</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/total-voting-rights-918</guid>
<pubDate>Wed, 01 Apr 2026 06:00:00 GMT</pubDate>
<description>EDX Medical Group plc has announced its total voting rights, stating that there are 411,844,583 ordinary shares of 1 pence each in issue, with each share carrying one vote. This figure serves as the denominator for shareholders to determine their notification obligations under the Financial Conduct Authority's Disclosure and Transparency Rules regarding their interests in the company's share capital.
Disclaimer*</description>
</item>
<item>
<title>Scottish Prostate Cancer Initiative</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/scottish-prostate-cancer-initiative</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/scottish-prostate-cancer-initiative</guid>
<pubDate>Wed, 25 Mar 2026 07:00:00 GMT</pubDate>
<description>EDX Medical Group plc has been appointed as the primary delivery partner for the Scottish Prostate Cancer Initiative, a new project aimed at enhancing early detection and diagnosis of prostate cancer. This initiative will offer free Prostate-Specific Antigen (PSA) testing to 25,000 men aged 40 to 80 across Scotland throughout the year, utilizing blood samples for analysis. The project will also deploy advanced diagnostic tests for selected groups to investigate genetic risk factors and other bio</description>
</item>
<item>
<title>Exercise of Warrants</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/exercise-of-warrants-93</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/exercise-of-warrants-93</guid>
<pubDate>Wed, 04 Mar 2026 16:05:00 GMT</pubDate>
<description>EDX Medical Group plc announced that a warrant holder has exercised warrants to acquire ordinary shares at an exercise price of 10p per share. Following this exercise, the Company will have 411,844,583 ordinary shares in issue, with newly issued shares expected to be admitted to trading on the Aquis Stock Exchange on March 10, 2026. The company retains 12,100,000 warrants at 10p and 12,500,000 warrants at 20p.
Disclaimer*</description>
</item>
<item>
<title>Total voting rights</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/total-voting-rights-919</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/total-voting-rights-919</guid>
<pubDate>Fri, 27 Feb 2026 14:55:00 GMT</pubDate>
<description>EDX Medical Group plc announced that it currently has 411,594,583 ordinary shares of 1 pence each in issue, with each share carrying one vote. This figure serves as the denominator for shareholders to calculate their notification requirements under the Financial Conduct Authority's Disclosure and Transparency Rules regarding their interests in the company's share capital.
Disclaimer*</description>
</item>
<item>
<title>Equity Fundraising raises £3.5 million</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/equity-fundraising-raises-pound35-million</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/equity-fundraising-raises-pound35-million</guid>
<pubDate>Mon, 16 Feb 2026 07:00:00 GMT</pubDate>
<description>EDX Medical Group plc has successfully raised £3.5 million through an equity fundraising, issuing 24,999,999 new ordinary shares at 14p each to existing high net worth shareholders. The net proceeds will accelerate the company's prostate cancer programme, focusing on developing diagnostic products and services. This follows a previous funding round in October 2025 which secured up to £4 million. Following this latest fundraising, the company's total voting rights will be 411,594,583 ordinary sha</description>
</item>
<item>
<title>Director dealing</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/director-dealing-151</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/director-dealing-151</guid>
<pubDate>Fri, 09 Jan 2026 07:00:00 GMT</pubDate>
<description>EDX Medical Group plc announced that Professor Sir Christopher Evans, founder and Chief Scientific Officer, purchased 41,780 ordinary shares on January 8, 2026, at 13.00 pence per share, following previous share purchases on January 2 and January 5, 2026. This latest transaction brings his total ownership to 136,161,523 shares, representing 35.22% of the issued share capital.
Disclaimer*</description>
</item>
<item>
<title>Interim report: Six months to 30 September 2025</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/interim-report-six-months-to-30-september-2025</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/interim-report-six-months-to-30-september-2025</guid>
<pubDate>Fri, 19 Dec 2025 12:00:00 GMT</pubDate>
<description>EDX Medical Group plc reported a loss for the six months ended September 30, 2025, of £2,292,168, an increase from the £1,699,298 loss in the prior year period, with administrative expenses rising due to investment in cancer diagnostics. The company experienced a delay in European market product availability affecting forecast revenues, though this has been resolved. Key developments included progress on prostate and testicular cancer diagnostics, a public-private partnership for a pneumonia tes</description>
</item>
<item>
<title>Commercial launch of bowel cancer testing service</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/commercial-launch-of-bowel-cancer-testing-service</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/commercial-launch-of-bowel-cancer-testing-service</guid>
<pubDate>Thu, 18 Dec 2025 07:00:00 GMT</pubDate>
<description>EDX Medical Group plc has commercially launched its BC95 bowel cancer testing service in the UK, which offers improved early detection with sensitivities exceeding 95% across all stages and includes an assessment of hereditary risk. This comprehensive service utilizes epigenetic biomarker testing, EarlyTect®-C, developed in partnership with Genomictree, alongside other methods like qFIT, to analyze biomarkers from faecal, blood, or saliva samples. The BC95 service aims to address the significant</description>
</item>
<item>
<title>EDX Medical secures up to £4million funding</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/edx-medical-secures-up-to-pound4million-funding</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/edx-medical-secures-up-to-pound4million-funding</guid>
<pubDate>Mon, 20 Oct 2025 06:00:00 GMT</pubDate>
<description>EDX Medical Group PLC announced it has secured funding of up to £4 million through a combination of a share placement and a convertible loan note. The company will issue 14,285,713 new ordinary shares at 14p per share, raising £2.0 million. Additionally, a new convertible loan note agreement for up to £2.0 million was agreed with Professor Sir Chris Evans. Following the issue of placing shares, Sir Chris will own 136,016,939 ordinary shares, representing 35.18% of the issued share capital. The f</description>
</item>
<item>
<title>Advance testicular cancer testing service launched</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/advance-testicular-cancer-testing-service-launched</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/advance-testicular-cancer-testing-service-launched</guid>
<pubDate>Tue, 07 Oct 2025 10:33:00 GMT</pubDate>
<description>EDX Medical Group PLC announced the commercial launch of its TC100 testicular cancer testing service in the UK. The TC100 service uses a blood sample to detect early signs of testicular cancer with high accuracy, incorporating unique micro-RNA biomarker reporting alongside traditional serum biomarkers. Clinical studies have demonstrated 100% success in detecting recurrence in post-treatment surveillance. Initial results from two patients showed the test confirmed one was clear of cancer with 99%</description>
</item>
<item>
<title>Result of Annual General Meeting</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/result-of-annual-general-meeting-201</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/result-of-annual-general-meeting-201</guid>
<pubDate>Mon, 29 Sep 2025 14:58:00 GMT</pubDate>
<description>EDX Medical Group PLC held its Annual General Meeting on September 29, 2025, where all 16 resolutions were passed. Resolutions 1 to 13 were ordinary resolutions, while resolutions 14 to 16 were special resolutions. Each resolution received 99.99% of votes in favor, with 179,034,268 votes for and 16,666 votes against. For resolutions 12, 14, and 15, 179,018,268 votes were cast for, 16,666 against, and 16,000 votes were withheld. As of September 29, 2025, the company has 372,308,871 ordinary share</description>
</item>
<item>
<title>Posting of Notice of AGM and Annual Report</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/posting-of-notice-of-agm-and-annual-report-1</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/posting-of-notice-of-agm-and-annual-report-1</guid>
<pubDate>Mon, 01 Sep 2025 06:00:00 GMT</pubDate>
<description>EDX Medical Group PLC announced that its annual general meeting (AGM) will be held on 29 September 2025 at 2:00 p.m. The meeting will take place at the Marcus Beck Library in London. The annual report and financial statements for the year ended 31 March 2025, along with the Notice of AGM and Form of Proxy, will be posted to eligible shareholders on 1 September 2025. Electronic copies of these documents will also be available on the Company's website shortly.
Disclaimer*</description>
</item>
<item>
<title>Publication - Annual Report & Financial Statements</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/publication-annual-report-and-financial-statements</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/publication-annual-report-and-financial-statements</guid>
<pubDate>Fri, 22 Aug 2025 14:33:00 GMT</pubDate>
<description>EDX Medical Group PLC published its Annual Report and Financial Statements for the year ending March 31, 2025, reporting revenue of £0.1 million and a loss of £3.6 million. The loss was higher than expected due to increased product development and a £200,000 provision for non-recurring items, partially offset by £0.5 million in finance income. Key highlights include the development of a new AI-powered prostate cancer diagnostic test, a March 2025 equity fundraising of £3 million at 14p per shar</description>
</item>
<item>
<title>Partnership formed to provide new pneumonia test</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/partnership-formed-to-provide-new-pneumonia-test</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/partnership-formed-to-provide-new-pneumonia-test</guid>
<pubDate>Fri, 08 Aug 2025 06:00:00 GMT</pubDate>
<description>Partnership formed to provide new pneumonia test.</description>
</item>
<item>
<title>Result of General Meeting</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/result-of-general-meeting-362</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/result-of-general-meeting-362</guid>
<pubDate>Thu, 03 Jul 2025 12:04:00 GMT</pubDate>
<description>Result of General Meeting.</description>
</item>
<item>
<title>Posting of notice of General Meeting</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/posting-of-notice-of-general-meeting-4</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/posting-of-notice-of-general-meeting-4</guid>
<pubDate>Tue, 17 Jun 2025 06:00:00 GMT</pubDate>
<description>Posting of notice of General Meeting.</description>
</item>
<item>
<title>Memorandum of Understanding with Spire Healthcare</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/memorandum-of-understanding-with-spire-healthcare</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/memorandum-of-understanding-with-spire-healthcare</guid>
<pubDate>Mon, 16 Jun 2025 06:00:00 GMT</pubDate>
<description>Memorandum of Understanding with Spire Healthcare.</description>
</item>
<item>
<title>‘Bed & ISA’ share transfer</title>
<link>https://6ix.com/company/edx-medical-group-plc/news/bed-and-isa-share-transfer</link>
<guid isPermaLink="true">https://6ix.com/company/edx-medical-group-plc/news/bed-and-isa-share-transfer</guid>
<pubDate>Tue, 15 Apr 2025 06:00:00 GMT</pubDate>
<description>‘Bed & ISA’ share transfer.</description>
</item>
</channel>
</rss>